Effect of OPG gene mutation on protein expression and biological activity in osteoporosis
- Authors:
- Shuhui Qin
- Qiuping Zhang
- Li Zhang
View Affiliations
Affiliations: Department of Orthopedics, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China, Department of Urinary Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China, Department of Endocrinology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China
- Published online on: June 28, 2017 https://doi.org/10.3892/etm.2017.4712
-
Pages:
1475-1480
-
Copyright: © Qin
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The effect of an osteoprotegerin (OPG) gene mutation was investigated on its protein expression and biological activity in osteoporosis. The pcDNA3.0-OPG plasmid or wild-type plasmid were transfected into HEK293 cells. Osteoclast tartrate-resistant acid phosphatase (TRAP) staining and counting were then performed, and the expression of genes related to osteoclast differentiation and activation were measured by RT-PCR. The wild-type or mutant-type OPG at concentrations of 0, 10, 20, 50 and 100 ng/ml were added respectively to RAW264.7 cells and incubated for 24 h. The viability of cells treated with the wild-type and mutant-type OPG at a concentration of 100 ng/ml was still over 99%, which indicated that the wild-type and mutant-type OPG at this concentration had no cytotoxic effect on RAW264.7 cells. The number of TRAP-positive cells decreased with increasing concentration of wild-type or mutant-type OPG. At the concentrations of 20, 50 and 100 ng/ml, the inhibitory effect of wild-type OPG was significantly higher than that of mutant-type OPG (p<0.05). Both mutant-type and wild-type OPG inhibited the bone resorption activity of osteoclasts, and the inhibitory effect of wild-type OPG was significantly higher than that of mutant-type OPG at the concentrations of 20, 50 and 100 ng/ml (p<0.05). The levels of TRAP and RANK mRNA in the wild-type OPG treatment group were significantly lower than those in the control group, while the levels of TRAP and RANK mRNA in the mutant-type OPG treatment group were significantly lower than those in the wild-type group (p<0.05). The genetic mutation did not affect the protein expression levels of OPG, but inhibited the normal activity of OPG.
View References
|
1
|
McCormick RK: Osteoporosis: Integrating
biomarkers and other diagnostic correlates into the management of
bone fragility. Altern Med Rev. 12:113–145. 2007.PubMed/NCBI
|
|
2
|
Riasnyĭ VM, Apukhovs'ka LI, Velykyĭ MM,
Shymans'kyĭ IO, Labudzyns'kyĭ DO and Komisarenko SV:
Immunomodulatory effects of vitamin D3 and bisphosphonates in
nutritional osteoporosis in rats. Ukr Biokhim Zh (1999). 84:73–80.
2012.(In Ukrainian). PubMed/NCBI
|
|
3
|
Hwang JS, Chen JF, Yang TS, Wu DJ, Tsai
KS, Ho C, Wu CH, Su SL, Wang CJ and Tu ST: The effects of strontium
ranelate in Asian women with postmenopausal osteoporosis. Calcif
Tissue Int. 83:308–314. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hofbauer LC and Schoppet M:
Osteoprotegerin gene polymorphism and the risk of osteoporosis and
vascular disease. J Clin Endocrinol Metab. 87:4078–4079. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ohmori H, Makita Y, Funamizu M, Hirooka K,
Hosoi T, Orimo H, Suzuki T, Ikari K, Nakajima T, Inoue I, et al:
Linkage and association analyses of the osteoprotegerin gene locus
with human osteoporosis. J Hum Genet. 47:400–406. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dominguez LJ, Scalisi R and Barbagallo M:
Therapeutic options in osteoporosis. Acta Biomed. 81 Suppl 1:55–65.
2010.PubMed/NCBI
|
|
7
|
Montagnana M, Lippi G, Danese E and Guidi
GC: The role of osteoprotegerin in cardiovascular disease. Ann Med.
45:254–264. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brosch S, Redlich K and Pietschmann P:
Pathogenesis of osteoporosis in rheumatoid arthritis. Acta Med
Austriaca. 30:1–5. 2003.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yasuda H, Shima N, Nakagawa N, Mochizuki
SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, et
al: Identity of osteoclastogenesis inhibitory factor (OCIF) and
osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits
osteoclastogenesis in vitro. Endocrinology. 139:1329–1337. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wright HL, McCarthy HS, Middleton J and
Marshall MJ: RANK, RANKL and osteoprotegerin in bone biology and
disease. Curr Rev Musculoskelet Med. 2:56–64. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hofbauer LC, Kühne CA and Viereck V: The
OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet
Neuronal Interact. 4:268–275. 2004.PubMed/NCBI
|
|
12
|
Khosla S: Minireview: The OPG/RANKL/RANK
system. Endocrinology. 142:5050–5055. 2001. View Article : Google Scholar : PubMed/NCBI
|
